Beijing: Coronavirus vaccines developed in China may be ready for use by the general public in early November, an official from the China Center for Disease Control and Prevention (CDC) said.
There are four COVID-19 vaccines in the final phase of clinical trials in China. At least three of the required workers have already been introduced under an emergency-use program launched in July.
Phase 3 clinical trials were proceeding smoothly and vaccines could be ready for the general public in November or December, CDC chief biosafety expert Guizhen Wu said in an interview with State TV late Monday.
Wu, who said she has not experienced any unusual symptoms in recent months after taking an experimental vaccine in April, did not specify which vaccines she was referring to.
State pharmaceutical giant China National Pharmaceutical Group (Sinopharma) and a unit of the US-listed Synovac Biotech are developing three vaccines under the state’s Emergency Use Program. A fourth COVID-19 vaccine being developed by CanSino Biologics was approved for use by the Chinese military in June.
Sinpharma said in July that its vaccine could be ready for public use by the end of this year after the conclusion of Phase 3 trials.
Global vaccine manufacturers are in the running to develop an effective vaccine against the virus, killing more than 925,000 people. Western vaccine manufacturers earlier this month rejected any political pressure to maintain scientific study standards and push the process forward.
(This story has not been edited by NDTV employees and is auto-generated from a syndicated feed.)